Skip Navigation


Hum. Reprod. Advance Access originally published online on June 8, 2006
Human Reproduction 2006 21(9):2281-2289; doi:10.1093/humrep/del176
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
21/9/2281    most recent
del176v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ulziibat, S.
Right arrow Articles by Koji, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ulziibat, S.
Right arrow Articles by Koji, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Identification of estrogen receptor beta-positive intraepithelial lymphocytes and their possible roles in normal and tubal pregnancy oviducts

Shirendeb Ulziibat1,2, Kuniaki Ejima1, Yasuaki Shibata3, Yoshitaka Hishikawa1, Michio Kitajima2, Akira Fujishita2, Tadayuki Ishimaru2,5 and Takehiko Koji1,4

1 Division of Histology and Cell Biology, Department of Developmental and Reconstructive Medicine, Nagasaki University Graduate School of Biomedical Sciences 2 Department of Obstetrics and Gynecology, Nagasaki University School of Medicine and 3 Division of Oral Pathology and Bone Metabolism, Department of Developmental and Reconstructive Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

4 To whom correspondence should be addressed at: Division of Histology and Cell Biology, Department of Developmental and Reconstructive Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan. E-mail: tkoji{at}net.nagasaki-u.ac.jp

5 Present address: Sasebo Chuo Hospital, Sasebo, Nagasaki, Japan


    Abstract
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Acknowledgements
 References
 
BACKGROUND: Although intraepithelial lymphocytes (IELs) in human oviductal epithelium have been implicated in the regulation of local immunity, the precise kinetics and mechanism of steroid regulation of IEL are largely unknown. METHODS: We examined the localization of estrogen receptors (ERs) and progesterone receptors (PRs) in 41 human oviducts by immunohistochemistry. These tissues were obtained from various menstrual cycles, also from both post-menopausal women and tubal pregnancies. The expressions of ERbeta mRNA and membrane (m)PR mRNA were examined by in situ hybridization and RT–PCR, respectively. RESULTS: Most of the IEL expressed ERbeta at both mRNA and protein levels. The number of ERbeta-positive IEL, which were identified as CD8-positive T lymphocytes and also were mPR positive, was increased in the late proliferative, the mid-secretory and late secretory phases in normally cycling women (P < 0.05). Interestingly, in tubal pregnancy, ERbeta-positive IELs were consistently abundant. In addition, we found a high Ki-67-labelling index for IEL, although ER{alpha} was entirely absent in the tubal pregnancy oviducts. CONCLUSIONS: These results suggest that the number of IEL fluctuated because of estrogen and progesterone levels probably through ERbeta and mPR, respectively. ERbeta-positive IEL may be involved in regulating immune tolerance in tubal pregnancy oviducts.

Key words: estrogen receptors/human oviduct/intraepithelial lymphocytes/membrane progesterone receptor/tubal pregnancy


    Introduction
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Acknowledgements
 References
 
Intraepithelial lymphocytes (IELs) in human oviductal mucous membranes are involved in the regulation of local immune tolerance, such that sperm and blastocysts are transported through the oviduct without the activation of a local immune reaction (Kutteh et al., 1990Go). A dysfunctional local immunity may damage the epithelial function, including oviduct transportation. Mammalian oviduct consists of ciliated cells, secretory cells and basal cells (Verhage et al., 1979Go; Crow et al., 1994Go). Of these, the basal cells are considered unique and are morphologically characterized in rabbit oviduct as specialized lymphocytes (Odor, 1974Go). However, detailed knowledge of the IEL in human oviduct is limited. In particular, the responsiveness of the cell kinetics to sex steroids such as estrogen and progesterone would be worthy of analysis because the structure and function of oviduct are highly dependent upon steroid action.

Ectopic pregnancies are responsible for ~10% of all maternal mortality (Dorfman, 1983Go), among which 99% are tubal pregnancies occurring in the ampullaris part of the oviduct (Seifer et al., 1995Go). The major cause of tubal pregnancy is postulated to be the dysfunction of the ciliated cells due to various infectious diseases (Walters et al., 1988Go; McGee et al., 1999Go). However, the involvement of local immunity mediated by the IEL in this process is poorly understood. Moreover, serum levels of estrogen and progesterone are generally lower in patients with ectopic pregnancy, and the expression of estrogen receptor (ER){alpha} and progesterone receptor (PR) is also decreased, compared with normal pregnancy (Radwanska et al., 1978Go; Sadan et al., 2002Go).

Estrogen is crucial for maintaining the structure and function of various female reproductive organs via binding to specific classical nuclear ER{alpha} and the newly identified ERbeta (Kuiper et al., 1996Go). However, ERbeta may act via a molecular mechanism different from that of ER{alpha} in various tissues including reproductive organs such as uterus, ovary, mammary gland, prostate and intestine (Critchley et al., 2001Go; Lecce et al., 2001Go; Hishikawa et al., 2003Go, 2004Go; Tsurusaki et al., 2003Go; Kawano et al., 2004Go; Tamaru et al., 2004Go). In the normal epithelium and stroma of the human oviduct, ER{alpha} increases in the follicular phase, reaching a peak at mid-cycle and then decreasing in the late luteal phase (Amso et al., 1994Go). In contrast, expression studies of ERbeta in mammalian oviducts have yielded significant discrepancies (Saunders et al., 1997Go; Wang et al., 2000Go). Wang et al. (2000)Go reported no expression of ERbeta protein in the luminal epithelium of rat oviduct, whereas Taylor and Al-Azzawi (2000)Go reported ERbeta expression in the cytoplasm of ciliated epithelial and stromal cells in normal human oviduct, although they did not examine the menstrual cycle dependency of this expression pattern. Therefore, the precise role of ERbeta in normal and tubal pregnancy oviducts is not fully understood.

Progesterone is also a key component in the regulation of growth, development and function in female reproductive tissues via binding to PR (Brenner et al., 1991Go; Slayden et al., 1993Go; Noe et al., 1999Go; Gava et al., 2004Go). Classical PRs (PR A and PR B) are localized in the nuclei of epithelial and stromal cells but not IEL in mammalian and human oviducts (Amso et al., 1994Go; Christow et al., 2002Go; Sun et al., 2003Go; Ulbrich et al., 2003Go). Recently, the presence of membrane PR (mPR) was reported in the rat granulosa cells, in bovine corpus luteum cells of the female reproductive system and in human testis (Peluso et al., 2001Go; Bramley et al., 2002Go; Shah et al., 2005Go). However, the expression of mPR in human oviduct remains to be clarified.

This study aimed to clarify the population kinetics of IEL in human normal and tubal pregnancy oviducts and to clarify the menstrual cycle-dependent expression and localization of ER{alpha}, ERbeta and PR in human oviduct using in situ hybridization (ISH) and immunohistochemistry. We also examined the expression of mPR mRNA in the oviducts to understand the responsiveness to progesterone, by RT–PCR and ISH. On the basis of the findings, we discuss the possible role of ERbeta-positive IEL in the mucosal immune system in normal and tubal pregnancy oviducts.


    Materials and methods
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Acknowledgements
 References
 
Patients
Ampullaris parts of human oviduct were obtained from 41 patients with informed consent: 25 premenopausal patients (aged 35–49 years) with regular menstrual cycles (28-33 day intervals), eight post-menopausal patients (aged 52–78 years) who had undergone hysterectomy and bilateral salpingo-oophorectomy due to uterine fibroids and eight patients (aged 21–33 years) who underwent salpingoectomy for tubal pregnancy. None of the patients had been treated with any hormonal medications for a minimum of 3 months before tissue sampling. In all patients, accurate menstrual dating could be carried out according to the last and next menstrual periods and the basal body temperature. This was corroborated with appropriate histologic dating of endometrium as described previously (Gompel and Silverberg, 1994Go; Ishimaru et al., 2004Go; Khan et al., 2005Go).

The surgical specimens were classified according to menstrual cycle and histological examination into the following groups: early proliferative phase (n = 4), late proliferative phase (n = 8), early secretory phase (n = 4), mid-secretory phase (n = 5) and late secretory phase (n = 4). All specimens were collected in accordance with the guidelines of the Declaration of Helsinki and with the approval of the Nagasaki University Institutional Review Board.

Immunohistochemistry
Tissue samples were fixed in 4% paraformaldehyde (PFA; Merck, Darmstadt, Germany) in 10 mM phosphate-buffered saline (PBS) and embedded in paraffin using standard procedures. The tissues were cut into 4-µm-thick sections and were dewaxed with toluene and rehydrated through a graded ethanol series. The sections were autoclaved at 120°C for 15 min (except CD3) in 10 mM sodium citrate (pH 6.0). After the inhibition of endogenous peroxidase activity with 0.3% H2O2 in methanol for 15 min, the sections were pre-incubated with 500 µg ml–1 of normal goat IgG (Sigma Chemical, St Louis, MO, USA) and 1% bovine serum albumin in PBS for 1 h. Then, the sections were reacted with the primary antibodies (Table I) overnight. After washing with 0.075% Brij 35 in PBS, the sections were incubated with horse-radish peroxidase (HRP)-labelled goat anti-mouse IgG (1:100; Chemicon International, Temecula, CA, USA) or HRP-labelled goat anti-rabbit IgG (1:200; MBL, Nagoya, Japan) for 1 h. The sites of HRP were visualized with 3,3'-diaminobenzidine (DAB; Dojin Chemical Co., Kumamoto, Japan), Ni2+, Co2+ and H2O2. As a negative control, some sections were reacted with normal mouse or rabbit IgG (Sigma Chemical) at the same concentrations instead of the specific antibodies.


View this table:
[in this window]
[in a new window]

 
Table I. List of primary antibodies for immunohistochemistry

 
RNA isolation and RT–PCR of mPR mRNA
The oviduct tissue was frozen immediately with liquid nitrogen and crushed using a Multi-Beads Shocker (Yasui Kikai, Nagoya, Japan). Total RNA was extracted from the sample powder using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the instructions provided by the manufacturer. Aliquots of 2 µg of total RNA were reverse-transcribed with True Script II reverse transcriptase (Sawady Technology, Tokyo, Japan) in the presence of an oligo(dT) primer. Using a Light Cycler instrument (Roche Molecular Biochemicals, Mannheim, Germany), the cDNAs were amplified with specific primers and DNA Master SYBR Green I kit according to the instructions provided by the manufacturer. The primer sequences used for amplification were selected with the aid of Primer 3 software (Whitehead Institute for Biomedical Research, Cambridge, UK) and were as follows: forward, 5'-GTGCACCAAGAGCAAAGGAT-3'; reverse, 5'-GGAGAGCAAACACCTGTTCC-3'. The region of PCR amplification was 980–1487, GenBank accession no. NM_006667 [GenBank] ; Gerdes et al., 1998Go). Thus, the expected size of amplified DNA was 507 bp. Each PCR cycle consisted of denaturation at 94°C for 3 min, annealing at 55°C for 15 s and extension at 72°C for 40 s. Thirty-five cycles were performed, followed by a final extension at 72°C for 5 min. To confirm the specificity of the PCR product, the electrophoretic patterns of Hind III digests were analysed. Moreover, the corresponding PCR product was size-fractionated and subcloned into pGEM-T Easy Vector (Promega, Madison, WI, USA) to confirm the specificity of the PCR product. The PCR products were sequenced by CER 8000 Beckman Coulter, and the product of each primer pair was confirmed in both directions (forward and reverse). The PCR product was compared with published human mPR sequences by BLAST similarity search (http://www.ncbi.nlm.nih.gov), and we found 100% homology with the published mPR sequences (Gerdes et al., 1998Go).

Laser microdissection
Frozen sections (5–20 µm) of the oviducts were cut and mounted on glass slides covered with PEN foil (2.5 µm thick; Leica Microsystems, Wetzlar, Germany) for the microdissection system. The sections were stained with haematoxylin, followed by eosin and then air-dried. A part of the epithelium, stroma or the IEL was dissected from the frozen sections of the oviduct with the Laser microdissection (LMD) system, as described previously (Kolble, 2000Go). The samples were immediately placed into 30 µl of Trizol solution, and total RNA was extracted from the epithelium, stroma and IEL, as described above.

Preparation of oligo-DNA probes
A 45-base sequence corresponding to ERbeta mRNA, nucleotide no. 861-905 (Tsurusaki et al., 2003Go), and a 39-base sequence corresponding to human mPR cDNA, nucleotide no. 102-140, were selected (Gerdes et al., 1998Go). These antisense and sense sequences were synthesized together with two and three TTA repeats, at the 5' and 3' ends, and used as probes after haptenization with thymine–thymine (T–T) dimer, as described previously in detail (Koji and Nakane, 1996Go). The sequence of antisense probe for ERbeta was 5'-TTATTA-C ACTAGCTGCTCGGGGCTCAGGGCGTCCAGCAGCAGCTCCC GCAC-ATTATTATT-3' (Tsurusaki et al., 2003Go). The sequence of antisense probe for mPR was 5'-TTATTA-GGGTCGGCGCCAGT CGCCACCACATCCTCGGCAGCCAT-ATTATTATT-3'.

A computer-assisted search of GenBank for the above antisense and sense sequences revealed no significant homology with any known sequences. The T–T dimer was introduced into the oligo-DNAs by UV irradiation (254 nm) at a dose of 12 000 J m–2. The generation of T–T dimer was verified immunochemically using a mouse monoclonal HRP-labelled anti-T–T IgG (1:80; Kyowa Medex, Tokyo, Japan).

ISH for ERbeta and mPR mRNA
Before ISH, we performed dot-blot hybridization analysis to determine the specificity and sensitivity of the DNA probe (Yoshii et al., 1995Go; Koji and Nakane, 1996Go; Koji, 2000Go). Non-radioactive ISH was performed as described previously (Koji and Brenner, 1993Go; Yoshii et al., 1995Go; Koji and Nakane, 1996Go; Fujishita et al., 1997Go; Koji, 2000Go; Shirota et al., 2005Go). The sections were treated with 0.3% H2O2 in methanol for 15 min to inhibit endogenous peroxidase activity, followed by 0.2 N HCl for 20 min and 50 µg ml–1 of proteinase K (Wako Pure Chemicals, Osaka, Japan) at 37°C for 15 min. After post-fixation with 4% PFA in PBS, the sections were immersed in 2 mg ml–1 of glycine in PBS for 30 min and kept in 40% deionized formamide (Nacalai Tesque, Kyoto, Japan) in 4 x standard saline citrate (SSC) until used for hybridization. Hybridization was carried out for 15 h at 37°C with 2 µg ml–1 of T–T dimerized antisense oligo-DNA for ERbeta and mPR dissolved in the hybridization medium. Then, the slides were washed three times with 2 x SSC/50% formamide/0.075% Brij 35, twice with 0.5x SSC/50% formamide/0.075% Brij 35 and finally followed by 2 x SSC. The signals were detected immunohistochemically, as described previously (Koji and Brenner, 1993Go; Yoshii et al., 1995Go; Koji and Nakane, 1996Go; Fujishita et al., 1997Go; Koji, 2000Go; Shirota et al., 2005Go). In every run, consecutive tissue sections were hybridized with T–T dimerized ERbeta and mPR sense oligo-DNA as a negative control. To evaluate the level of hybridizable RNAs in the tissue sections, a 28S rRNA probe was used as a positive control (Yoshii et al., 1995Go). Furthermore, some sections were hybridized with antisense probe in the presence of an excess amount of unlabelled antisense or unlabelled sense probe to provide definitive evidence for the sequence specificity of the signal.

Statistical analysis
For quantitative analysis, more than 2000 cells were counted in random fields at x400 magnification, and the number of IEL, ERbeta-positive and Ki-67-positive cells was expressed as a percentage of positive cells per total number of counted cells. The number of IEL positive for Ki-67 and CD8 was counted in more than 200 IELs and expressed as a percentage of positive cells per total number of counted cells. Cell counts were performed in a blind fashion by three individuals. The data are expressed as mean ± SEM. Differences between groups were examined for statistical significance using the Student’s t-test. P < 0.05 denoted a statistically significant difference. All analyses were performed with a statistical software package (StatView, version 5.0; Abacus Concepts, Berkeley, CA, USA).


    Results
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Acknowledgements
 References
 
Immunohistochemical identification of lymphocyte markers in the IEL
To confirm the IEL cell type, we performed immunohistochemistry for T- and B-lymphocyte markers. The T-lymphocyte cell marker (T-supressor), CD8, was detected in all IEL (Figure 1A). Most of the IELs showed co-staining for CD3 (pan-T cell) (data not shown). However, no staining was detected for either CD4 (T helper) or CD20 (B-lymphocyte marker) (data not shown).


Figure 1
View larger version (45K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Figure 1. Immunohistochemical analysis of T lymphocytes in oviduct during mid-secretory phase. Oviduct tissue sections were incubated with anti-CD8 antibody (A) or normal mouse IgG (B) as a negative control. Arrows indicate the CD8-positive intraepithelial lymphocytes (IEL) of human oviduct. Scale bar = 20 µm. Original magnification x400. (C) Quantitative analysis of IEL per epithelial cells during menstrual cycling, in post-menopausal and tubal pregnancy oviducts. Data are presented as the mean ± SEM. *P < 0.05.

 
Kinetics of IEL density
Next, we performed quantitative analysis of the IEL. The percentage of IEL per total number of epithelial cells was increased in the late proliferative (9.2 ± 0.6%) and late secretory (8.9 ± 0.5%) menstrual phase and in tubal pregnancies (9.1 ± 0.5%), whereas there was a significant decrease in the proportion of IEL in the early secretory phase (5.3 ± 1.1%) and post-menopausal (6.7 ± 0.6%) specimens (Figure 1C).

Immunohistochemical localization of Ki-67 and CD8 in human oviduct
The IEL were then immunostained for Ki-67, a marker of proliferating cells. Ki-67 was localized in the nuclei of the IEL and secretory cells of the epithelium (Figure 2A and C) and all of the Ki-67-positive IEL co-expressed CD8 (Figure 2B and D). The labelling index revealed a marked increase in Ki-67-positive IEL in tubal pregnancy (6.1 ± 0.5%), early proliferative phase (4.5 ± 0.5%) and late secretory phase cases (3.5 ± 0.9%) than in the post-menopausal women (1.0 ± 0.2%) (Figure 2E). In contrast, the index of secretory cells was increased in the late proliferative-phase (5.0 ± 0.9%), early secretory-phase (5.5 ± 1.5%) and tubal pregnancy (4.4 ± 1.4%) cases but significantly decreased in the early proliferative (0.7 ± 0.5%) and late secretory phases (0.8 ± 0.5%) (Figure 2F).


Figure 2
View larger version (40K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Figure 2. Immunohistochemical analysis of Ki-67 and CD8 in the oviduct of premenopausal women. The panels were obtained from the late proliferative phase (A and B) and from the late secretory phase (C and D). Arrows indicate Ki-67-positive cells in the intraepithelial lymphocytes (IEL) (A and C). Ki-67 and CD8 were co-localized in the same IEL in serial sections (AD). Scale bar = 20 µm. Original magnification x400. Quantitative analysis of Ki-67-positive IEL (E) and Ki-67-positive secretory cells (F) during menstrual cycling, in post-menopausal and tubal pregnancy oviducts. Data are presented as the mean ± SEM. *P < 0.05, **P < 0.001.

 
Immunohistochemical localization of ER{alpha}, ERbeta and PR in human oviduct
Immunohistochemistry of ER{alpha}, ERbeta and PR in the premenopausal, post-menopausal and tubal pregnancy oviducts revealed staining for ER{alpha} and PR in the nuclei of secretory epithelial cells but not in the ciliated cells, IEL or endothelial cells during the normal menstrual cycle (Figure 3). The staining intensity for ER{alpha} and PR was very high in the late proliferative phase but was significantly decreased in the mid-secretory phase (Figure 3A, C, D and F). However, the expression of these proteins in the oviduct epithelial cells was almost completely lost in post-menopausal women, whereas the stroma retained the same levels as during menstrual cycling (Figure 3G and I). In tubal pregnancies, ER{alpha} was not found in any cell of the oviduct, whereas PR was expressed in the secretory cells and stromal cells but not in IEL (Figure 3J and L).


Figure 3
View larger version (118K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Figure 3. Immunohistochemical analysis of estrogen receptor (ER){alpha} , ERbeta and progesterone receptor (PR) in human oviduct during the menstrual cycle, post-menopause and tubal pregnancy. Oviduct tissue sections were reacted with anti-ER{alpha} (A, D, G and J), anti-ERbeta (B, E, H and K) and anti-PR (C, F, I and L). The panels were obtained from the late proliferative phase (AC), from the mid-secretory phase (D–F) of the menstrual cycle, from post-menopausal women (GI) and tubal pregnancy (JL). Arrows indicate positive cells. ER{alpha} and PR disappeared in the epithelial cells but not the stromal cells in post-menopausal women compared with premenopausal women (G and I). In tubal pregnancy, ER{alpha} disappeared from epithelium and stroma (J), whereas PR was expressed in the epithelium and stroma (L). ERbeta was expressed strongly in the intraepithelial lymphocytes (IEL), secretory cells, endothelial cells and some stromal cells of premenopausal, post-menopausal women and tubal pregnancy (B, E, H and K). S, secretory cell; E, endothelial cell; St, stroma; Ep, epithelium. Scale bar = 20 µm. Original magnification x400.

 
In contrast, ERbeta expression was predominantly seen in the nuclei of IEL and secretory cells, weakly detected in the cytoplasm of secretory cells and not detected in the ciliated cells (Figure 3B, E, H and K). Virtually all of the IEL were ERbeta-positive, and the intensity of ERbeta staining was much stronger in these cells than in the secretory cells. ERbeta was also localized in the stromal cells and vascular endothelial cells. Interestingly, ERbeta-positive IEL and stromal cells were abundant in tubal pregnancy oviducts (Figure 3K); however, there was no substantial difference in the intensity of ERbeta staining between premenopausal and post-menopausal oviducts; ERbeta was still detected in the epithelial and stromal cells of post-menopausal oviduct (Figure 3H). Quantitative analysis of the ERbeta-positive IEL staining revealed similar data to that shown in Figure 1C because all IELs were positive for ERbeta (data not shown).

ISH of ERbeta mRNA in human oviduct
Next, we performed ISH for ERbeta mRNA to examine its synthesis. As shown in Figure 4A, ERbeta mRNA was localized in the IEL, epithelial cells, stromal cells and vascular endothelial cells of the oviduct tissue. Mirror sections indicated that the cellular distribution of ERbeta mRNA was essentially similar to that of ERbeta protein (Figure 4B). No significant staining was detected when adjacent sections were reacted with the sense probe (Figure 4C). In addition, when adjacent sections were hybridized with ERbeta antisense probe in the presence of a 100-fold excess amount of unlabelled corresponding antisense oligo-DNA, the signal for ERbeta mRNA was markedly decreased (Figure 4D).


Figure 4
View larger version (89K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Figure 4. Localization of estrogen receptor (ER)beta by in situ hybridization and immunohistochemistry in mirror sections of oviduct during mid-secretory phase. (A) ERbeta antisense thymine–thymine (T–T) dimerized oligo-DNA probe. ERbeta mRNA was strongly expressed in the intraepithelial lymphocytes, epithelial cells and some stromal cells. (B) Expression of ERbeta protein in the oviduct. (C) ERbeta sense T–T dimerized oligo-DNA probe as a negative control. (D) Competition assay; the section was hybridized with ERbeta antisense probe in the presence of a 100-fold excess amount of unlabelled corresponding antisense oligo-DNA. Arrows indicate cells positive for ERbeta mRNA (A) and ERbeta protein (B). Scale bar = 20 µm. Original magnification x400.

 
Kinetics of CD8-positive IEL and its correlation with ERbeta-positive IEL
Approximately 90.5 ± 3.0% of the IEL showed immunostaining for CD8 during the normal menstrual cycle, in post-menopausal and in tubal pregnancy oviducts (Figure 5A). Moreover, to clarify the association between the expression of CD8 and ERbeta, we immunostained serial sections of IEL during menstrual cycles. As shown in Figure 5B, all CD8-positive IELs were also ERbeta positive (Figure 5C).


Figure 5
View larger version (45K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Figure 5. Quantitative analysis of CD8-positive intraepithelial lymphocytes (IEL) per total IEL during menstrual cycling in post-menopausal and tubal pregnancy oviducts. Immunohistochemical analysis of CD8 and ERbeta in oviduct during mid-secretory phase. Arrows indicate that CD8 (B) and ERbeta (C) were co-localized in the same IEL in serial sections. Scale bar = 20 µm. Original magnification x400.

 
Expression of mPR mRNA in human oviduct detected by RT–PCR using LMD and ISH
To address the possible mechanism by which progesterone regulates IEL proliferation, we examined the expression of mPR mRNA, because PR A and PR B were not detected in the IEL (Figure 6). RT–PCR to assess whether mPR mRNA is expressed in human oviduct tissue revealed a single band of 507 bp (Figure 6A). A control sample without reverse transcriptase revealed that the extract was free of genomic mPR DNA contamination. The specificity of the PCR product was confirmed by digestion with Hind III, revealing two fragments of 325 and 182 bp (Figure 6A). Next, we localized mPR mRNA in the epithelial and stromal parts of the oviduct tissue, which were separated by LMD. The staining intensity of the 507-bp band was much higher in the epithelial cells than in the stroma (Figure 6B). To clarify whether IEL express mPR mRNA, the IELs (about 100 cells) were dissected by LMD and the extract was analysed by RT–PCR, revealing a significant band of 507 bp, as expected (Figure 6C).


Figure 6
View larger version (34K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Figure 6. (A) RT–PCR analysis of membrane progesterone receptor (mPR) mRNA in extracts of human oviduct tissue in secretory phase. M, DNA molecular weight marker; 1, mPR mRNA; 2, a negative control with no cDNA. The PCR product was digested with Hind III, producing two DNA fragments of 325 and 182 bp (3). (B) RT–PCR analysis of mPR mRNA in extracts of epithelium (Ep) and stroma (St) from the human oviduct in secretory phase. (C) RT–PCR analysis of mPR mRNA in extracts from intraepithelial lymphocytes (IEL) of human oviduct in secretory phase.

 
Finally, we identified mPR mRNA-positive cells in the sections of human oviduct by ISH. Before the experiment, we confirmed the sensitivity and specificity of the probes by dot-blot hybridization and determined that the T–T dimerized mPR antisense oligo-DNA could detect down to 10-pg mPR sense DNA specifically (data not shown). ISH of the oviductal sections of the secretory phase localized mPR mRNA in IEL, secretory cells and some stromal cells but not in ciliated cells (Figure 7B). The transcript staining intensity was markedly higher in the IEL than in the secretory cells. Moreover, the intensity of signal in the IEL did not change during the menstrual phases (data not shown). No significant staining was detected when adjacent sections were hybridized with the sense probe (Figure 7C). In addition, when adjacent sections were hybridized with mPR antisense probes in the presence of a 100-fold excess amount of unlabelled corresponding antisense oligo-DNA, the signal was markedly decreased (Figure 7D).


Figure 7
View larger version (130K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Figure 7. In situ localization of membrane progesterone receptor (mPR) mRNA expression in the oviduct during secretory phase. (A) 28S rRNA complementary oligo-DNA. (B) mPR mRNA antisense oligo-DNA. (C) mPR sense oligo-DNA. (D) Competition assay; the section was hybridized with mPR mRNA antisense probe in the presence of a 100-fold excess amount of unlabelled corresponding antisense oligo-DNA. Arrows indicate positive cells. Scale bar = 20 µm. Original magnification x400.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Acknowledgements
 References
 
This study provides new information regarding the expression and localization of ERbeta mRNA and protein in normal human oviduct during the menstrual cycling. We found that ERbeta was specifically co-expressed in CD8-positive IEL and secretory cells of the epithelium. Interestingly, the number of ERbeta-positive IEL in the oviducts fluctuated depending on the menstrual cycles and seemed to increase in a progesterone-dependent manner. This increase was probably mediated via mPR, the expression of which was reported for the first time in oviductal epithelial cells including IEL. Moreover, in oviduct from cases of tubal pregnancy, the number of ERbeta-positive IEL was increased significantly, possibly indicating damage to the local immune system in the oviduct.

A better understanding of the function and hormonal regulation of the oviduct epithelium is important for reproductive biology because the normal transport of sperm and blastocysts through the oviduct relies on the inhibition of local immunity (Kutteh et al., 1990Go). IELs in human oviduct are positive for CD8 and CD3 (Kutteh et al., 1990Go). Moreover, CD8-positive IELs are also expressed in normal intestine (Brimnes et al., 2005Go) where they play a possible role in mediating immune tolerance to luminal antigens by suppressing the immune response. In this study, we show for the first time that the CD8-positive IELs in human oviduct were also positive for ERbeta. ERbeta expression has also been reported in the infiltrating leucocytes of the rat vagina (Wang et al., 2000Go) and human cervix (Stygar et al., 2001Go); therefore, we postulated that the IEL in oviduct epithelia might play a key role in the inflammatory response causing tubal pregnancy (Witkin, 2002Go). In our study, the number of ERbeta-positive IEL was increased significantly in the tubal pregnancy samples, whereas ER{alpha} was not found in the epithelium or stroma of any tubal pregnancy oviducts (eight cases). Sadan et al. (2002)Go also reported that ER{alpha} was expressed in only one case of the 12 tubal pregnancy oviducts. This finding implicates ERbeta, but not ER{alpha}, as a dominant hormonal player in the oviduct of tubal pregnancies. It may therefore be proposed that differential expression of ER{alpha} and ERbeta in tubal pregnancy oviduct is involved in the abnormal transport of the fertilized oocyte into the uterus.

It is well known that plasma levels of estrogen increase during the proliferative phase of the menstrual cycle, whereas progesterone levels increase during the secretory phase (Palter and Olive, 2002Go). This study revealed that the population density of ERbeta-positive IEL altered biphasically in premenopausal women; one peak was in the proliferative phase, and the other was in the mid-secretory and late secretory phases. These results may indicate that the proliferative-phase peak of IEL is mediated by estrogen via ERbeta, whereas the peak in the mid-secretory and late secretory phases indicates possible regulation of IEL by progesterone via PR. As classical PR A and PR B were not detected in the IEL during the menstrual cycle, we examined the involvement of a new type of PR, mPR, which is localized in the cell membrane (Peluso et al., 2001Go; Bramley et al., 2002Go; Shah et al., 2005Go). Indeed, mPR mRNA was detected in the oviduct IEL. We also found that the number of Ki-67-positive IEL correlated exactly with ERbeta and mPR expression and was significantly increased in the early proliferative phase and the late secretory phase. Interestingly, in tubal pregnancy oviducts, the number of Ki-67- and ERbeta-positive IEL increased significantly, probably reflecting an increased proliferation of IEL possibly mediated via ERbeta. Taken together with these results, our findings indicate that the fluctuation and the proliferative activity of IEL in the premenopausal oviduct may be associated with the plasma levels of estrogen via ERbeta and progesterone via mPR, respectively.

In conclusion, we found that the IEL of human oviduct expressed ERbeta and mPR and that the number of IEL fluctuated, probably because of estrogen levels in the proliferative phase and progesterone levels during the secretory phase. Furthermore, our study strongly implicated the possible involvement of ERbeta-positive IEL in regulating immune function in normal and tubal pregnancy oviducts.


    Acknowledgements
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Acknowledgements
 References
 
We thank Dr Keiko Shukuwa for excellent technical assistance (Division of Histology and Cell Biology, Department of Developmental and Reconstructive Medicine, Nagasaki University Graduate School of Biomedical Sciences) and Dr Koichi Hiraki for sample collection (Department of Obstetrics and Gynecology, Nagasaki University School of Medicine). This study was supported in part by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Science, Sports and Culture (nos 1247003, 15390058 and 16659047).


    References
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Acknowledgements
 References
 
Amso NN, Crow J, Shaw RW. (1994) Comparative immunohistochemical study of oestrogen and progesterone receptors in the fallopian tube and uterus at different stages of the menstrual cycle and the menopause. Hum Reprod 9:1027–1037.[Abstract/Free Full Text]

Bramley TA, Menzies GS, Rae MT, Scobie G. (2002) Non-genomic steroid receptors in the bovine ovary. Domest Anim Endocrinol 23:3–12.[CrossRef][ISI][Medline]

Brenner RM, McClellan MC, West NB, Novy MJ, Haluska GJ, Sternfeld MD. (1991) Estrogen and progestin receptors in the macaque endometrium. Ann N Y Acad Sci 622:149–166.[Medline]

Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L. (2005) Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 174:5814–5822.[Abstract/Free Full Text]

Christow A, Sun X, Gemzell-Danielsson K. (2002) Effect of mifepristone and levonorgestrel on expression of steroid receptors in the human Fallopian tube. Mol Hum Reprod 8:333–340.[Abstract/Free Full Text]

Critchley HO, Brenner RM, Henderson TA, Williams K, Nayak NR, Slayden OD, Millar MR, Saunders PT. (2001) Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J Clin Endocrinol Metab 86:1370–1378.[Abstract/Free Full Text]

Crow J, Amso NN, Lewin J, Shaw RW. (1994) Morphology and ultrastructure of fallopian tube epithelium at different stages of the menstrual cycle and menopause. Hum Reprod 9:2224–2233.[Abstract/Free Full Text]

Dorfman SF. (1983) Deaths from ectopic pregnancy, United States, 1979 to 1980. Obstet Gynecol 62:334–338.[Abstract]

Fujishita A, Nakane PK, Koji T, Masuzaki H, Chavez RO, Yamabe T, Ishimaru T. (1997) Expression of estrogen and progesterone receptors in endometrium and peritoneal endometriosis: immunohistochemical and in situ hybridization study. Fertil Steril 67:856–864.[CrossRef][ISI][Medline]

Gava N, Clarke CL, Byth K, Arnett-Mansfield RL, deFazio A. (2004) Expression of progesterone receptors A and B in the mouse ovary during the estrous cycle. Endocrinology 145:3487–3494.[Abstract/Free Full Text]

Gerdes D, Wehling M, Leube B, Falkenstein E. (1998) Cloning and tissue expression of two putative steroid membrane receptors. Biol Chem 379:907–911.[ISI][Medline]

Gompel C and Silverberg SG. (1994) Cyclical variation of endometrium. In Gompel C and Silverberg SG (Eds.). Pathology of Gynecology and Obstetrics(Lippincott, Philadelphia, PA) pp. 171–205.

Hishikawa Y, Damavandi E, Izumi S, Koji T. (2003) Molecular and histochemical analysis of estrogen receptors {alpha} and beta expressions in the mouse ovary: in situ hybridization and southwestern histochemistry. Med Electron Microsc 36:67–73.[Medline]

Hishikawa Y, Tamaru N, Ejima K, Hayashi T, Koji T. (2004) Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2. Arch Histol Cytol 67:455–464.[CrossRef][ISI][Medline]

Ishimaru T, Khan KN, Fujishita A, Kitajima M, Masuzaki H. (2004) Hepatocyte growth factor may be involved in cellular changes to the peritoneal mesothelium adjacent to pelvic endometriosis. Fertil Steril 81:810–818.[Medline]

Kawano N, Koji T, Hishikawa Y, Murase K, Murata I, Kohno S. (2004) Identification and localization of estrogen receptor {alpha}- and beta-positive cells in adult male and female mouse intestine at various estrogen levels. Histochem Cell Biol 121:399–405.[CrossRef][ISI][Medline]

Khan KN, Masuzaki H, Fujishita A, Kitajima M, Sekine I, Matsuyama T, Ishimaru T. (2005) Estrogen and progesterone receptor expression in macrophages and regulation of hepatocyte growth factor by ovarian steroids in women with endometriosis. Hum Reprod 20:2004–2013.[Abstract/Free Full Text]

Koji T. (2000) Springer Laboratory Manual: Molecular Histochemical Techniques(Springer-Verlag, Tokyo).

Koji T and Brenner RM. (1993) Localization of estrogen receptor messenger ribonucleic acid in rhesus monkey uterus by nonradioactive in situ hybridization with digoxigenin-labeled oligonucleotides. Endocrinology 132:382–392.[Abstract]

Koji T and Nakane PK. (1996) Recent advances in molecular histochemical techniques: in situ hybridization and southwestern histochemistry. J Electron Microsc 45:119–127.[Abstract/Free Full Text]

Kolble K. (2000) The LEICA microdissection system: design and applications. J Mol Med 78:24–25.

Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925–5930.[Abstract/Free Full Text]

Kutteh WH, Blackwell RE, Gore H, Kutteh CC, Carr BR, Mestecky J. (1990) Secretory immune system of the female reproductive tract II. Local immune system in normal and infected fallopian tube. Fertil Steril 54:51–55.[ISI][Medline]

Lecce G, Meduri G, Ancelin M, Bergeron C, Perrot-Applanat M. (2001) Presence of estrogen receptor beta in the human endometrium through the cycle: expression in glandular, stromal and vascular cells. J Clin Endocrinol Metab 86:1379–1386.[Abstract/Free Full Text]

McGee ZA, Jensen RL, Clemens CM, Taylor-Robinson D, Johnson AP, Gregg CR. (1999) Gonococcal infection of human fallopian tube mucosa in organ culture: relationship of mucosal tissue TNF-alpha concentration to sloughing of ciliated cells. Sex Transm Dis 26:160–165.[ISI][Medline]

Noe M, Kunz G, Herbertz M, Mall G, Leyendecker G. (1999) The cyclic pattern of the immunocytochemical expression of oestrogen and progesterone receptors in human myometrial and endometrial layers: characterization of the endometrial-subendometrial unit. Hum Reprod 14:190–197.[Abstract/Free Full Text]

Odor DL. (1974) The question of "basal" cells in oviductal and endocervical epithelium. Fertil Steril 25:1047–1062.[ISI][Medline]

Palter SF and Olive DL. (2002) Reproductive physiology. In Berek JS (Ed.). Novak’s Gynecology 13th edn (Lippincott Williams & Wilkins, Philadelphia, PA) pp. 160–161.

Peluso JJ, Fernandez G, Pappalardo A, White BA. (2001) Characterization of a putative membrane receptor for progesterone in rat granulosa cells. Biol Reprod 65:94–101.[Abstract/Free Full Text]

Radwanska E, Frankenberg J, Allen EI. (1978) Plasma progesterone levels in normal and abnormal early human pregnancy. Fertil Steril 30:398–402.[ISI][Medline]

Sadan O, Ginath S, Rotmensch S, Boaz M, Golan A, Glezerman M. (2002) Role of steroid receptors in the pathogenesis of tubal pregnancy. J Reprod Med 47:1031–1034.[ISI][Medline]

Saunders PTK, Maguire SM, Gaughan J, Millar MR. (1997) Expression of estrogen receptor beta (ERbeta) in multiple rat tissues visualized by immunohistochemistry. J Endocrinol 154:13–16.

Seifer DB, DeCherney AH, Bartimus J, Frickleton J. (1995) Complications of early pregnancy. In O’Grady JP, Gimovsky ML, McIlhargie CJ (Eds.). Operative Obstetrics(Williams & Wilkins, Baltimore, MD) pp. 4–5.

Shah C, Modi D, Sachdeva G, Gadkar S, Puri C. (2005) Coexistence of intracellular and membrane-bound progesterone receptors in human testis. J Clin Endocrinol Metab 90:474–483.[Abstract/Free Full Text]

Shirota K, Tateishi K, Koji T, Hishikawa Y, Hachisuga T, Kuroki M, Kawarabayashi T. (2005) Early human preantral follicles have relaxin and relaxin receptor (LGR7), and relaxin promotes their development. J Clin Endocrinol Metab 90:516–521.[Abstract/Free Full Text]

Slayden OD, Hirst JJ, Brenner RM. (1993) Estrogen action in the reproductive tract of rhesus monkeys during antiprogestin treatment. Endocrinology 132:1845–1856.[Abstract]

Stygar D, Wang H, Vladic YS, Ekman G, Eriksson H, Sahlin L. (2001) Co-localization of estrogen receptor beta and leucocyte markers in the human cervix. Mol Hum Reprod 7:881–886.[Abstract/Free Full Text]

Sun X, Christow A, Marions L, Gemzell-Danielsson K. (2003) Progesterone receptor isoform B in the human fallopian tube and endometrium following mifepristone. Contraception 67:319–326.[CrossRef][ISI][Medline]

Tamaru N, Hishikawa Y, Ejima K, Nagasue N, Inoue S, Muramatsu M, Hayashi T, Koji T. (2004) Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. Lab Invest 84:1460–1471.[CrossRef][ISI][Medline]

Taylor AH and Al-Azzawi F. (2000) Immunolocalization of estrogen receptor beta in human tissues. J Mol Endocrinol 24:145–155.[Abstract]

Tsurusaki T, Aoki D, Kanetake H, Inoue S, Muramatsu M, Hishikawa Y, Koji T. (2003) Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J Clin Endocrinol Metab 88:1333–1340.[Abstract/Free Full Text]

Ulbrich SE, Kettler A, Einspanier R. (2003) Expression and localization of estrogen receptor {alpha}, estrogen receptor beta and progesterone receptor in the bovine oviduct in vivo and in vitro. J Steroid Biochem Mol Biol 84:279–289.[CrossRef][ISI][Medline]

Verhage HG, Bareither ML, Jaffe RC, Akbar M. (1979) Cyclic changes in ciliation, secretion and cell height of oviductal epithelium in women. Am J Anat 156:505–521.[CrossRef][ISI][Medline]

Walters MD, Eddy CA, Gibbs RS, Schachter J, Holden AE, Pauerstein CJ. (1988) Antibodies to Chlamydia trachomatis and risk for tubal pregnancy. Am J Obstet Gynecol 159:942–946.[ISI][Medline]

Wang H, Eriksson H, Sahlin L. (2000) Estrogen receptors {alpha} and beta in the female reproductive tract of the rat during the estrous cycle. Biol Reprod 63:1331–1340.[Abstract/Free Full Text]

Witkin SS. (2002) Immunological aspects of genital chlamydia infections. Best Pract Res Clin Obstet Gynaecol 16:865–874.[CrossRef][Medline]

Yoshii A, Koji T, Ohsawa N, Nakane PK. (1995) In situ localization of ribosomal RNAs is a reliable reference for hybridizable RNA in tissue sections. J Histochem Cytochem 43:321–327.[Abstract]

Submitted on March 10, 2006; resubmitted on April 18, 2006; accepted on April 25, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
A. Cvoro, D. Tatomer, M.-K. Tee, T. Zogovic, H. A. Harris, and D. C. Leitman
Selective Estrogen Receptor- Agonists Repress Transcription of Proinflammatory Genes
J. Immunol., January 1, 2008; 180(1): 630 - 636.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
21/9/2281    most recent
del176v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ulziibat, S.
Right arrow Articles by Koji, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ulziibat, S.
Right arrow Articles by Koji, T.
Social Bookmarking